drugset / Trial / NCT06372496

Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma

NCT06372496

Phase 4 Active not recruiting 1366 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this study is to assess and compare the effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult participants with uncontrolled asthma

Timeline

Start
2024-04-16
Primary completion
2025-07-28
Completion
2027-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone Furoate Other / unclassified
Subject Umeclidinium Other / unclassified
Subject Vilanterol Other / unclassified

Indications